The historical rank and industry rank for Insight Molecular Diagnostics's FCF Margin % or its related term are showing as below:
IMDX'
s FCF Margin % Range Over the Past 10 Years
Min: -5209.6 Med: -1654 Max: -625.62
Current: -1409.7
During the past 13 years, the highest FCF Margin % of Insight Molecular Diagnostics was -625.62%. The lowest was -5209.60%. And the median was -1654.00%.
IMDX's FCF Margin % is ranked worse than 95.1% of 204
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.845
vs IMDX: -1409.70
Insight Molecular Diagnostics FCF Margin % Related Terms
Insight Molecular Diagnostics FCF Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Insight Molecular Diagnostics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Insight Molecular Diagnostics FCF Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Insight Molecular Diagnostics's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Insight Molecular Diagnostics's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Insight Molecular Diagnostics (IMDX) has a FCF Margin % of -25,787.50% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Insight Molecular Diagnostics and its competitors. According to the industry distribution chart, Insight Molecular Diagnostics ranks #194 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 95.1%.
Is Insight Molecular Diagnostics' FCF Margin % too high?
Insight Molecular Diagnostics' current FCF Margin % is -25,787.50%. Based on the distribution chart, Insight Molecular Diagnostics ranks #194 out of 204 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Insight Molecular Diagnostics has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Insight Molecular Diagnostics' FCF Margin % compare to BDSX and XGN?
According to the Medical Diagnostics & Research industry distribution chart, Insight Molecular Diagnostics ranks #194 out of 204 companies for FCF Margin %. This places Insight Molecular Diagnostics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Diagnostics & Research company?
A good FCF Margin % depends on the Medical Diagnostics & Research industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Insight Molecular Diagnostics and its competitors. Insight Molecular Diagnostics's current FCF Margin % is -25,787.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insight Molecular Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Insight Molecular Diagnostics (IMDX) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.26, compared to a current price of $5.42 — trading 330.2% above its estimated fair value. The current FCF Margin % is -25,787.50%. Insight Molecular Diagnostics' overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Insight Molecular Diagnostics (IMDX), the current FCF Margin % is -25,787.50% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Insight Molecular Diagnostics (IMDX) Overvalued in 2026?
Based on GuruFocus' analysis, Insight Molecular Diagnostics stock appears to be overvalued.
The current stock price of $5.42 is trading 330.2% above its estimated GF Value™ of $1.26.
GuruFocus considers Insight Molecular Diagnostics to be Significantly Overvalued.
Key valuation signals for IMDX:
FCF Margin %: -25,787.50%
GF Value™: $1.26 vs. price of $5.42 (330.2% above fair value)
No single metric tells the full story. See the IMDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Insight Molecular Diagnostics Business Description
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.
49GF Score
Get the complete analysis for IMDX
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IMDX has been successfully added to your 
